SNPMiner Trials (Home Page)
Report for Clinical Trial NCT04507919
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      The purpose of this Cohort Treatment Plan is to allow access to trametinib and dabrafenib for
      eligible patients diagnosed with BRAF V600activating mutation-positive advanced NSCLC. The
      patient's Treating Physician should follow the suggested treatment guidelines and comply with
      all local health authority regulations.
    
Name: Dabrafenib and Trametinib
Description: The starting dose of the combination treatment will be administered as follows:
Dabrafenib, 150 mg, twice daily (BID);
Trametinib, 2.0 mg, once daily (QD)
 Type: Drug
 Name: Dabrafenib
Description: If a dose reduction below 50 mg BID for dabrafenib is required, dabrafenib will be permanently discontinued, but the patient will be allowed to continue trametinib.
 Type: Drug
 Name: Trametinib
Description: If a dose reduction below 1.0 mg once daily for trametinib is required, then trametinib will be permanently discontinued, but the patients will be allowed to continue dabrafenib.
 Type: Drug
There is one SNP
SNPs
1 V600E 
Stage IIIB, Stage IV) NSCLC (Non-Small Cell Lung Cancer) with confirmed BRAF
             V600E/K activating mutation. --- V600E ---